BRIEF YALE REPORTS has used human plasmin clinically as a debriding agent in open wounds involving joints and reports good results, with no adverse action on articular cartilage. Our purpose was to investigate this paradox.
Purified chondromucoprotein (CMP) was prepared from calf nasal cartilage7 and incubated with human plasmin** as illustrated in Figure 1 .
This shows that human plasmin has marked viscosity-reducing action in vitro against a major component of cartilage in its purified form. However, repeated intra-articular injections of 5,000 units of plasmin twice weekly into the knee joints of six dogs and six rabbits for a period of six or more weeks showed no changes in the articular cartilage. Six more rabbits were subjected to surgical laceration of the lateral capsules of the knee joints, and contusion of the cartilage surface of the lateral femoral condyle with a bone punch. Again, repeated injections of plasmin for six weeks produced no changes grossly or histologically when compared with the controls. Also, slices of articular and costal cartilage from groups of four rabbits, dogs and human patients were incubated with 7,000 units of plasmin for 24 to 48 hours, at 37°C. with constant agitation in various media (including oxygenated or non-oxygenated saline or tris buffered saline or Tyrode's solution, under sterile conditions). Though a little surface fraying was seen, no definite gross or microscopic changes in the slices could be found. Finally, normal human articular and costal cartilage slices were incubated with and without 7,000 units of human plasmin, and analyzed for ester sulfate by a method we have previously described.! As seen in Table 1 , both sets lost ester sulfate, but the control lost more than the plasmintreated strips. While part of this loss is from splitting of ester sulfate itself,' electrophoresis of the two incubation media (0.05 ml. each on Whatman #1 paper using acetate buffer at pH 4.3, room temperature, 1,000 volts for one hour, and stained when dry with toluidine blue) both produce about equal metachromatic spots with the identical mobility of chondroitin sulfate A. It is possible that the presence of antiplasmin or other inhibitor,8 present in vivo or with the cartilage slices, prevented plasmin from exerting destructive effects it is known to have on purified CMP.' However, the electrophoretic results suggest that there may be in the cartilage itself an agent which can split chondroitin sulfate bonds. This possibility is now being investigated.
In conclusion, plasmin is not likely to be involved in the in vivo degradation of CMP, and conversely, the use of plasmin as a debriding agent in open wounds involving joints probably does not endanger articular cartilage.
